GlassScriptPhysician profile
Blake R Beazer
NPI 1073510012
$6,962.87
in general payments reported to CMS, 2019-2025
52 companies · $787 in 2025
The $787 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $1,072 · 2021: $1,174 · 2022: $997 · 2023: $927 · 2024: $1,048 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,743 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,742.70 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $837.92 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $636.85 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $529.90 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $512.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $360.16 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.86 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $297.63 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $263.17 | 2019-2023 | |
| Pfizer INC. | $209.15 | 2021-2025 | |
| Astellas Pharma US INC | $197.14 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $176.02 | 2019-2022 | |
| Allergan, INC. | $173.62 | 2019-2020 | |
| Comsort, INC | $150.00 | 2019 | |
| Abbott Laboratories | $149.56 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $148.77 | 2021-2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Beazer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.